โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

SPEARHEAD-3 Pediatric Study

Sponsored by Adaptimmune

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Feb 9, 2026

Phase

Clinical Trial

Sponsor

Adaptimmune

Enrollment Target

20

Start Date

Sep 2023

๐Ÿ“Š
1 of 20 participants interested
5% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Who Can Participate

Inclusion Criteria

Subject has histologically confirmed diagnosis of any one of the following cancers: (A) Synovial Sarcoma (SS), (B) MPNST, (C) Neuroblastoma, or (D) Osteosarcoma (OS).
Age: (A) Synovial Sarcoma: 2 to 17 years (B) MPNST, Neuroblastoma and Osteosarcoma: 2 to 21 years
Body weight โ‰ฅ 10 kg
Must have previously received a systemic chemotherapy
Measurable disease prior to lymphodepletion according to RECIST v1.1 (or INCR, 2017 Neuroblastoma only).
HLA-A\*02 positive
Tumor shows MAGE-A4 expression confirmed by central laboratory.
Performance Status: (A) Subjects โ‰ฅ16: Eastern Cooperative Oncology Group (ECOG) 0 or 1 (B) Subjects 2 to 16: Lansky score โ‰ฅ 80 โ€ข Subject has anticipated life expectancy of greater than 3 months in the opinion of the investigator.

Exclusion Criteria

Positive for HLA-A\*02:05 in either allele; or any A\*02 having same protein sequence as HLA-A\*02:05
History of allergic reactions attributed to compounds of similar chemical

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

20 participants

๐ŸŽ‚

Age Range

2 Years - 21 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

Adaptimmune

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Palo Alto

California

Location available
View Palo Alto location page
RECRUITING

Bethesda

Maryland

Location available
View Bethesda location page
NOT_YET_RECRUITING

Boston

Massachusetts

Location available
View Boston location page
RECRUITING

St Louis

Missouri

Location available
View St Louis location page
NOT_YET_RECRUITING

New York

New York

Location available
View New York location page
NOT_YET_RECRUITING

Durham

North Carolina

Location available
View Durham location page
RECRUITING

Cincinnati

Ohio

Location available
View Cincinnati location page
RECRUITING

Philadelphia

Pennsylvania

Location available
View Philadelphia location page
NOT_YET_RECRUITING

Seattle

Washington

Location available
View Seattle location page

๐Ÿ“ And 1 more location available

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Leukemia Trials by City

Browse all leukemia clinical trials in these cities โ€” not just this study.

Looking for I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating. Treatment in Palo Alto?

Join others in California exploring innovative treatment options through clinical research

I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating. Treatment Options in Palo Alto, California

If you're searching for I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating. treatment in Palo Alto, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Palo Alto, Bethesda, Boston and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating.. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 20 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating.?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating.

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This I cannot determine the primary condition from the provided information. The only condition listed is "GENETIC:Afamitresgene autoleucel" which appears to be a treatment designation rather than a medical condition, and there are no keywords or meaningful summary details provided to identify what condition this pediatric study is actually treating. Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05642455. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.